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Abstract
RNA-based vaccines represent an interesting immunization modality, but suffer from poor stability and a lack of efficient
and clinically feasible delivery technologies. This study evaluates the immunogenic potential of naked in vitro transcribed
Semliki Forest virus replicon RNA (RREP) delivered intradermally in combination with electroporation. Replicon-immunized
mice showed a strong cellular and humoral response, contrary to mice immunized with regular mRNA. RREP-elicited
induction of interferon-c secreting CD8+ T cells and antibody responses were significantly increased by electroporation.
CD8+ T cell responses remained substantial five weeks post vaccination, and antigen-specific CD8+ T cells with phenotypic
characteristics of both effector and central memory cells were identified. The immune response during the contraction
phase was further increased by a booster immunization, and the proportion of effector memory cells increased significantly.
These results demonstrate that naked RREP delivered via intradermal electroporation constitute an immunogenic, safe and
attractive alternative immunization strategy to DNA-based vaccines.
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Introduction
Since its introduction in the early 1990s, nucleic acid-based
vaccination has emerged as a promising approach to elicit both
cellular and humoral immune responses [1,2]. Major advantages
include relatively low production cost, high stability, ease of
manipulation and the possibility to express complex antigens such
as transmembrane proteins.
Although most focus has been on plasmid-based DNA vaccines,
the use of RNA has advantages. For instance, the theoretical risk
of vector integration into the host genome and subsequent
malignant cell transformation is omitted. Due to the relatively
short half-life of the RNA molecule, expression is transient. This
decreases the risk when using tumor-associated antigen genes such
as proto-oncogenes for immunization. In addition, RNA-based
therapeutics is not classified as gene therapy by regulatory
authorities, facilitating a more rapid advance into clinical trials
of vaccine candidates.
The use of both naked and liposome-encapsulated mRNA has
been validated in animal models for induction of antibodies and
cytotoxic T lymphocytes (CTL) targeting cancer and infectious
diseases [3,4,5,6,7]. Vaccination of cancer patients in two Phase I
Clinical trials also demonstrated safety as well as increased cellular
or humoral immunity in some patients, respectively [8,9].
However, mRNA-elicited immune responses have often been
weak and required multiple immunizations. Thus far, perhaps the
most promising form of RNA vaccination is based on ex vivo tumor
antigen-transfected autologous bone marrow-derived dendritic
cells (DC) that are readminstered to the patient (reviewed in [10]).
This approach has demonstrated induction of immunological
responses in clinical trials with cancer patients and has in some
cases been associated with tumor regression [11]. Albeit an
attractive therapeutic avenue, personalized vaccines are not the
path towards prophylactic immunization of the masses. Preventive
vaccination requires fast and reliable administration in the field,
without the need for complex medical infrastructure.
We have previously developed suicidal viral vectors, DNA and
naked RNA vectors based on the alphavirus Semliki Forest virus
(SFV) replicon [12,13,14,15]. Upon transfection and nuclear
localization, the DNA launched replicon (DREP) is transcribed
from a Cytomegalovirus (CMV) promoter and exported to the
cytoplasm. Once in the cytoplasm, the DREP, viral particle
delivered replicon and naked RNA replicon (RREP) amplification
steps are identical (described in more detail in [16]). First, the 59
two thirds of the genome encoding the four replicase genes is
translated. The replicase complex amplifies the genomic RNA and
later transcribes large amounts of antigen-encoding mRNA from
the 26S subgenomic viral promoter located downstream of the
replicase genes. In addition to high expression levels of the inserted
antigen encoding gene, the various RNA-species produced by the
replicon amplification provide potent immunostimulatory ligands
to pattern recognition receptors (PRR) such as TLR3, PKR and
MDA-5 [17,18]. The antiviral program initiated by replicon
amplification and PRR signaling results in type I interferon
production and induces apoptosis [19,20,21], thereby promoting
cross-priming of antigen epitopes on MHC class I [22]. In
addition, alphavirus replicon RNA has an increased stability due
to its secondary structure, which protects it from degradation [23].
Accordingly, the replicon design has proven to be highly
immunogenic, typically only needing one immunization to elicit
a strong immune response contrary to conventional nucleic acid-
based vaccines [12,13,14].
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replicon intradermally by needle injection, inducing a potent
immune response [12]. The skin has a relatively high proportion of
professional antigen presenting cells such as Langerhans cells and
skin-resident DC, thus offering an attractive target tissue for
immunization. In vivo electroporation is a technological advance-
ment that has been used to augment in vivo transfection efficiency
and subsequent gene expression from nucleic acids injected into
the muscle [24,25]. Contrary to intramuscular (i.m.) electropora-
tion, intradermal (i.d.) electroporation is non-invasive, causes only
minimal pain and is well tolerated [26,27]. Currently, needle-free
delivery methods are being developed further streamlining the use
of this technology.
In this study, we investigated the potency of naked RNA to elicit
an immune response by administering RNA replicon-based
immunogens. We demonstrate that RREP, but not mRNA, is
able to elicit both strong humoral and cellular immune responses
that could be increased by electroporation. Thus, we present an
alternative to mRNA and DNA-based vaccines with an improved
safety and immunogenicity profile.
Methods
Plasmid construction, DNA and RNA preparation
DREP-tLuc, DREP-b-gal, pGEM-tLuc, pGEM-b-gal and
pCMV-tLuc were produced by standard molecular cloning
techniques. Plasmids were grown in E.coli and purified using the
Endofree Plasmid Mega Kit (#12381, Qiagen GmbH, Hilden,
Germany). RNA in vitro transcription was made from these
plasmids using the mMessage mMachine SP6 (AM1340, Ambion,
Invitrogen). All RNAs were purified using the RNeasy Mini Kit
(#74104, Qiagen) prior to immunizations. All constructs used for
immunizations are summarized in Table 1.
Mice and immunizations
C57BL/6 and 129sv/ew mice were bred and kept at the MTC
animal facilities at Karolinska Institutet, Stockholm, Sweden, in
accordance with the recommendations of the National Board for
Laboratory Animals and used at the age of 6–9 weeks. The
protocol was approved by the Northern Stockholm Board for
Laboratory Animal Ethics, protocol number N374/08. Prior to
immunization, mice were shaved on their lower back and
anesthetized with 4% isoflurane. 20 ml of RNA or DNA diluted
in PBS were injected intradermally (i.d.) to each flank in the lower
part of the back followed by immediate electroporation (E.P.) with
Derma Vax
TM Clinical DNA Vaccine Delivery System (Cellectis
SA, Romainville, France) at the injection sites. Electroporation
consisted of 2 pulses of 1.125 V/cm for 50 ms, and 8 pulses of
275 V/cm for 10 ms. The needle-array electrodes (NE-4-4) with
two parallel rows of four 2-mm pins (1.564 mm gaps) were used
for electroporation.
In vivo bioluminescence imaging
To monitor in vivo luciferase protein expression, 129sv/ew mice
were injected i.p. with 1.5 mg D-luciferin (Caliper Life Sciences,
Hopkinton, MA) diluted in PBS to a final volume of 100 ml and
anesthetized with isoflurane. In vivo luciferase expression, measured
as photonic emissions (photons/s/cm
2) using an in vivo imaging
system 100 (IVIS 100; Caliper Life Sciences), was performed
17 minutes after administration of luciferin (the signal peaked
17 minutes after injection, data not shown). Using the Living
Image software (version 2.50.1; Caliper Life Sciences) image
acquisition parameters were set at 10 seconds exposure time and
medium binning. The intensity of the luminescence within the
region of interest was quantified using the same software.
Background luminescence was determined by measuring lumines-
cence from naive mice. To calculate the integrated luciferase
signal between two time points the following formula was used:
(t22t1)(s2+(s12s2)/2) where t1 is timepoint 1, t2 timepoint 2, s1
signal at timepoint 1 and s2 signal at timepoint 2. To calculate the
total accumulated signal, integrated signals from all time points
were added up to the last time point of measurement (150 hours
post immunization). These calculations are further clarified in
Figure S1.
Determination of antigen-specific IFN-c secreting cells
Spleens were ground through a 70 mm cell grinder (Becton,
Dickinson and company, Franklin Lakes, NJ) in a petri dish with
5 ml RPMI-1640 (Sigma-Aldrich Co, St Louis, Mo) supplemented
with penicillin-streptomycin 100 units/ml (Gibco #15140, Invi-
trogen), L-glutamine 0.3 ml/ml (Gibco #25030, Invitrogen) and
5% heat inactivated FCS (Gibco #10270-106, Invitrogen). The
cells were centrifuged at 400 g at room temperature for 7 minutes
before they were resuspended in red cell lysis buffer (Sigma-
Aldrich). Lysis was carried out for 2 minutes and the lymphocytes
were subsequently washed and resuspended in RPMI-1640. Cells
were seeded (200,000 per well) with 2 mg/ml SIINFEKL peptide
(ProImmune Ltd, Oxford, United Kingdom) or 2.5 mg/ml ConA
(Sigma-Aldrich Co) as a positive control in 96-well filter plates
(Millipore) coated with anti-IFN-c antibodies (Mabtech, Nacka,
Sweden). Cells were then cultured for 20 hours at 37uC, 5% CO2
and developed as recommended by the manufacturer using
biotinylated anti-IFN-c, streptavidin-alkaline phosphatase and
the substrate BCIP-NBT Plus (Mabtech). The spot number was
enumerated and analyzed using the CTL ImmunoSpot reader and
ImmunoSpot software (Cellular Technology Ltd., OH).
Determination of anti-b-galactosidase IgG in serum
ELISA plates (Maxisorp, Nunc, Denmark) were coated with
50 ml/well of 1 mg/ml b-galactosidase (#10105031001, Roche
Diagnostic GmBH, Mannheim, Germany) in 0.1 M carbonate
buffer. The covered plates were incubated at 4uC over night. Next
day, the plates were washed five times with PBS containing 0.05%
Tween-20 (PBS-Tween), and blocked with 5% milk in PBS
(100 ml/well) for 3 h at room temperature. Thereafter, mouse
serum serially diluted from 1/200 to 1/204800 in PBS-Tween was
added (50 ml/well) to the wells, and the plates were incubated at
4uC over night. The plates were again washed five times with PBS-
Tween, and 50 ml horse radish peroxidase conjugated anti-mouse
total IgG (Southern Biotech, Birmingham, AL) diluted 1/5000 in
PBS-Tween was added to each well. After incubation for 3 h at
room temperature, the plates were washed with PBS-Tween and
Table 1.
Name Description
mRNA-tLuc in vitro transcribed mRNA encoding luciferase
RREP-tLuc in vitro transcribed RNA replicon encoding luciferase
DREP-tLuc DNA launched replicon encoding luciferase
pCMV-tLuc DNA encoding luciferase under a CMV promoter
mRNA-b-gal in vitro transcribed mRNA encoding b-galactosidase
RREP-b-gal in vitro transcribed RNA replicon encoding b-galactosidase
DREP-b-gal DNA launched replicon encoding b-galactosidase
doi:10.1371/journal.pone.0029732.t001
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reaction was stopped after 7 min with 25 ml 1 M HCl. The
absorbance was measured at 490 nm, using a VICTOR
2 1420
Multilabel Counter (PerkinElmer, Waltham, MA). Endpoint titers
were calculated according to the method described by Frey [28] or
at the dilution when the absorbance fell below 0.2.
Intracellular cytokine staining
Splenocytes were stimulated with the SIINFEKL peptide (1 mg/ml)
and GolgiPlug (BD Biosciences, Stockholm, Sweden) for 4 h. Surface
and intracellular stainings were performed using the Cytofix/
Cytoperm
TM Fixation/Permeabilization Solution set (BD Biosciences)
according to the manufacturer’s instructions. Anti-CD8, IFN-c,T N F
and IL-2 antibodies were purchased from BD Biosciences. Samples
were analyzed on a FACSCanto II cytometer (BD Biosciences) and
the data were processed using FlowJo (Tree Star, Ashland, OR).
Analyses of memory T cell subsets
Antibodies directed against CD8, CD27, CD62L (BD Biosci-
ences), CD43 (BioLegend, Nordic Biosite, Ta ¨by, Sweden), and
CD127 (eBioscience, AH Diagnostics ab, Ska ¨rholmen, Sweden), as
well as an H-2Kb/SIINFEKL pentamer (Proimmune, Oxford,
UK) were used for immunoflorescence staining and subsequent
flow cytometry analysis. Nonspecific binding was blocked by
adding FITC-conjugated rat anti-mouse CD16/CD32 antibody
(BD Biosciences). FITC-conjugated rat anti-mouse CD4 and
CD19 (BD Biosciences) were also used to exclude cells specific for
these markers from the analysis. Samples were analyzed on a
FACSCanto II cytometer (BD Biosciences) and the data were
processed using FlowJo (Tree Star).
Statistics
Statistical analyses were performed using GraphPad Prism
version 5.02 for Windows, GraphPad Software (San Diego
California, USA). The Mann-Whitney test was used for statistical
comparisons. A p-value of 0.05 or less was considered as significant.
Results
Immunization constructs
Plasmids used for direct immunizations or as templates for in
vitro transcription of RNA were constructed using standard cloning
techniques. Four vector modalities with two different inserts were
used in this study: in vitro transcribed mRNA, RREP (an in vitro
transcribed SFV RNA replicon), DREP (a DNA-launched SFV
replicon) and pCMV (a conventional DNA expression plasmid), as
listed in Table 1. For the assessment of cellular immune responses
a gene segment coding for the strong CD8+ T cell restricted MHC
class I epitope derived from ovalbumin (SIINFEKL) was attached
to the 39 end of the luciferase gene (mRNA-tLuc, RREP-tLuc and
DREP-tLuc). Constructs used to elicit a humoral immune
response contained the lacZ gene encoding b-galactosidase (b-
gal), a common reporter gene and inducer of antibody responses in
vivo. All plasmids were sequenced and biochemically verified for
expression in vitro (data not shown).
Intradermal injection of replicon RNA induces a cellular
immune response which is improved by electroporation
We first determined the immune response induced in mice after
a single i.d. immunization with mRNA-tLuc, RREP-tLuc or
DREP-tLuc with or without electroporation (E.P.). Ten days post
immunization, mice were sacrificed and purified splenocytes were
stimulated with the SIINFEKL epitope peptide and the number of
antigen-specific interferon-c (IFN-c) producing CD8+ T cells was
analyzed by ELISpot. I.d. injection of RREP-tLuc in combination
with E.P. generated a robust response and resulted in an almost
two-fold increase (p,0.05) in the number of IFN-c producing spot
forming CD8+ T cells as compared to non-E.P. mice. For DREP-
tLuc, the positive effect of E.P. was even more pronounced and
gave a 12-fold increase (p,0.001). Neither the naı ¨ve control
group, nor the groups that received an i.d. immunization with 5 or
40 mg mRNA-tLuc developed any detectable specific immune
responses (Figure 1a).
Figure 1. Immune responses after electroporation. (a) Antigen-specific IFN-c positive CD8
+ T cells per million splenocytes ten days after
intradermal immunization either with or without electroporation. Electroporation significantly increases the number of positive cells in RREP-tLuc and
DREP-tLuc immunized animals (p,0.05 and p,0.001 respectively). Data shows average number of positive cells from two separate experiments with
error bars showing standard error of the mean. The total number of mice analyzed is indicated in parenthesis above each bar. (b) ELISA for total anti-
b-galactosidase IgG antibody responses in sera from immunized mice 14 days post immunization. Electroporation significantly increases the antibody
responses for both RREP-b-gal and DREP-b-gal (p,0.001). Data are plotted as reciprocal end-point titers and shown for each individual mouse. The
total number of mice analyzed is indicated in parenthesis and the percentage of responding mice is indicated above each group. Abbreviations:
SFC=spot forming cells, E.P.=electroporation, and Ab=antibody.
doi:10.1371/journal.pone.0029732.g001
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immune response which is improved by electroporation
To investigate if E.P. also improved humoral immune responses
to administered RNA replicons, mice were injected with RREP-b-
gal (1 or 5 mg), DREP-b-gal (5 mg) or mRNA-b-gal (1 or 5 mg) i.d.
with or without E.P. Fourteen days post immunization, antibody
titers in sera from immunized mice were measured by ELISA. The
anti-b-galactosidase IgG endpoint titers were significantly in-
creased by E.P. (p,0.001) in groups immunized both with the
higher and lower dose of RREP-b-gal and in the DREP-b-gal
group (Figure 1b). However, no specific antibody response could
be detected in groups immunized with mRNA-b-gal.
Relative expression levels and cellular immune response
The amount of antigen produced in vivo from a specific vaccine
vector may be of importance for the magnitude of the immune
response. In order to correlate the induction of interferon-c
secreting CD8+ T cells to the relative amount of antigen produced
in vivo by different RNA and DNA vectors, we measured the
relative expression levels of several immunization constructs over
time. Mice were immunized with luciferase-encoding RREP-tLuc
(0.2, 1 or 5 mg), DREP-tLuc (0.2, 1 or 5 mg), mRNA-tLuc (5 mg) or
pCMV-tLuc (5 mg) by i.d. injection followed by E.P. Luciferase
activity was monitored repeatedly over a 6 day period using an in
vivo imaging system (Figure 2a) and the accumulated luciferase
production over the test period was calculated for each individual
mouse. All immunizations resulted in in vivo luciferase activity,
where the accumulated signal in DREP-tLuc, the two highest
concentrations of RREP-tLuc and pCMV-tLuc immunized
groups were within the same order of magnitude (Figure 2b).
Mice immunized with the low dose of RREP-tLuc and mRNA-
tLuc had a considerably lower accumulated luciferase activity. In
the mRNA-tLuc immunized group this was due to a short-lived
steadily declining luciferase expression, whereas the luciferase
activity of all other groups initially increased for a few days and
then declined towards the end of the experiment (Figure 2a). The
CD8+ T cell responses in these animals were determined by
ELISpot analysis 10 days post immunization. High numbers of
antigen specific IFN-c positive splenocytes were recorded for the
high doses of DREP-tLuc and RREP-tLuc, while pCMV-tLuc
produced a considerably lower response (Figure 2c). Again,
mRNA-tLuc did not elicit any detectable specific immune
response although a substantial luciferase activity had been
recorded (Figure 2b).
Intradermal injection of replicon RNA followed by
electroporation induces a cellular memory immune
response which is further increased by a booster
immunization
To investigate whether a cellular memory immune response
could be induced by the replicons, mice were immunized with
RREP-tLuc or DREP-tLuc in combination with E.P. Five weeks
after the immunization, tLuc-immunized mice were sacrificed and
subjected to ELISpot analysis as described above. In a parallel
study aiming at showing the effect of a booster injection, mice were
immunized twice five weeks apart and then sacrificed after five
more weeks and subjected to ELISpot analysis. Both RREP-tLuc
and DREP-tLuc elicited SIINFEKL-specific CD8+ T cells that
remained during the contraction phase of the cellular immune
response (Figure 3a). The booster immunization gave a statistically
significant increase (p,0.05) of antigen-specific CD8+ T cells in
animals immunized with DREP-tLuc, while we observed a trend
of an increase of these cells in RREP-tLuc immunized mice
Figure 2. In vivo antigen expression and the immune response
after electroporation. (a) Luciferase activity at different time points
measured in photons/s/cm
2. Data shows average activity for each group
and error bars indicate SEM (number of mice per group indicated in
Figure 2b). (b) Cumulative luciferase activity measured in photons/cm
2.
Data shows averageaccumulated luciferase activity up to 150 hours post
immunization for each group (number of mice per group indicated in
parentheses above each bar) with error bars showing standard error of
the mean. (c) Antigen-specific IFN-c positive CD8
+ T cells per million
splenocytes 10 days post-immunization. Data shows average number of
positive cells with error bars showing standard error of the mean. The
total number of mice analyzed is indicated in parenthesis and the
percentage of responding mice is indicated above each group.
doi:10.1371/journal.pone.0029732.g002
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for antigen specific CD8+ T cells using an H-2Kb/SIINFEKL
pentamer (Figure S2a).
The induction and maintenance of polyfunctional CD8+ T cells
contributes to effective antiviral immunity [29,30,31,32]. There-
fore we determined the presence of antigen-specific CD8+ T cells
capable of producing one or more cytokines in response to
stimulation with the SIINFEKL peptide by intracellular cytokine
staining for IFN-c, TNF and IL-2 followed by flow cytometry
analysis (Figure 3b). The total number of responding cells
increased significantly between the prime and the boost both for
RREP and DREP immunized mice (p,0.01).
Splenocytes from these animals were further analyzed by staining
antigen-specific CD8+ T cells for memory markers (CD127 and
CD62L, Figure S2b). Both effector (TEM; CD127
+CD62L
2)a n d
central memory CD8+ T( T CM; CD127
+CD62L
+) cell subsets [33]
were found in all immunized mice. A booster immunization led to a
significant increase of TEM cells in both RREP-tLuc (p,0.005) and
DREP-tLuc immunized animals (p,0.005), as shown in Figure 3c.
Thus, a proportion of the remaining antigen-specific CD8+ T cells
five weeks post immunization represents memory cells with a high
effector capacity.
Discussion
This study describes a new method of delivering naked Semliki
Forest virus RNA replicons that promotes strong cellular and
humoral immune responses. We have previously established that
i.m. delivery of in vitro transcribed naked RNA-replicons (RREP)
can elicit protective immunity in vivo [13]. Intradermal delivery of
DREP also induces a potent immune response [12], and here we
report that the same holds for naked RREP and that this response
can be further improved by topical E.P. In contrast, i.d. mRNA-
immunized mice failed to induce any detectable immune
responses. Contrary to previously reported studies with mRNA
vaccines that elicited immune responses, we have used a single
immunization of naked RNA [4,5,34]. RREP and mRNA differ in
many intrinsic properties which could explain their difference in
immunogenicity. A key difference is that once inside a cell, RREP
amplifies with subsequent high levels of antigen expression. This is
in contrast to mRNA which gives a relatively much lower antigen
expression. The stability differs between mRNA and RREP with
mRNA generally having a very short half-life in vivo whereas
alphavirus replicon RNA has a predicted highly ordered structure
and is partially resistant to degradation [23]. In addition,
alphavirus genomes have repetitive RNA elements in the 39
untranslated region (UTR) that prevent deadenylation [35] by
recruiting HuR, a cellular regulator of mRNA stability [36].
Efforts to improve stability, in vivo half-life and reporter-gene
expression in conventional mRNA has been made by adding
Venezuelan Equine Encephalitis virus-derived UTR [37]. Indeed,
luciferase activity after mRNA-tLuc in vivo E.P. is decaying rapidly
resulting in a substantial reduction of accumulated antigen
expression as compared to the equivalent dose of RREP-tLuc
(Figure 2a and 2b). The difference in antigen expression between
the vectors is further underscored if one considers the difference in
molar mass between mRNA-tLuc (,0.7 MDa) and RREP-tLuc
(,3.0 MDa). However, interpreting the measured luciferase
expression levels in vivo is not straightforward since the lumines-
cence only reflects the steady state, i.e. how much functional
luciferase that can be detected at the time of analysis. We do not
know if the rate of luciferase degradation differs between mice
immunized with the different vectors, hence we cannot completely
accurately estimate the total amount of luciferase expressed. For
example, replicon-containing vectors might via efficient induction
of innate signaling attract more cytotoxic immune cells resulting in
increased luciferase sequestration, thereby making us underesti-
mate the total expression in RREP-tLuc relative to mRNA-tLuc
immunized mice.
Another reason why RREP, but not mRNA, induces an
immune response could be that cellular mRNAs lack several of the
immunostimulatory properties that most viral RNA possess.
Although single stranded mRNA vaccines activate TLR7 signaling
[5], SFV replication turns on additional immune signaling from
several PRR sensing various forms of RNA species present in
endosomes and in the cytoplasm of the host cell such as TLR3,
MDA5, PKR and, to a lesser extent, RIG-I [17,18]. Subsequent
downstream signaling results in type I interferon production that
links innate and adaptive immune responses, and promotes both
antibody production, CD4+ helper T-cell induction and cytotoxic
immune responses. Replicon-based vectors are thus provided with
inherent adjuvant properties. The adjuvant effect becomes evident
Figure 3. Cellular immune response 5 weeks post immunization. (a) Antigen-specific IFN-c positive CD8
+ T cells per million splenocytes, (b)
Proportion responding CD8
+ T cells as determined by intracellular staining of IFN-c, IL-2 and TNF after SIINFEKL-peptide stimulation, or (c) proportion
effector memory CD8
+ T cells (pentamer H-2Kb/SIINFEKL positive CD8
+CD62L
2CD127
+ cells) 5 weeks after the last intradermal immunization in
combination with electroporation. Mice were either given one immunization (165 mg) or two immunizations 5 weeks apart (265 mg). Data shows
average number of positive cells with error bars showing standard error of the mean. A booster immunization significantly increased the cellular
memory response for both RREP-tLuc and DREP-tLuc (p,0.01). The total number of mice per group is indicated in parenthesis above each bar.
doi:10.1371/journal.pone.0029732.g003
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response between RREP-tLuc and pCMV-tLuc. Despite a higher
accumulated luciferase activity in pCMV-tLuc, it still elicits a
significantly lower immune response in our experimental system
(Figure 2). In studies using conventional DNA vaccines, increased
in vitro expression has translated into improved cellular immune
responses [38]. Indeed, in direct comparisons DNA-launched
alphavirus replicons have been shown to increase antigen
expression in vitro as compared to conventional plasmid DNA
vectors [12,15,20]. However, the difference in antigen expression
has been small (two–five-fold) and does not solely account for the
improved immunogenicity, since replicon DNA has induced
similar immune responses at up to 600-fold lower doses than
conventional DNA vaccines. Presented in this study is a direct
comparison of antigen expression in the skin of mice over time,
and it is evident from this data that the accumulated in vivo
expression levels from a conventional DNA expression vector and
a DNA-launched replicon are within the same order of magnitude.
These results indicate that it is the vaccine modality, and not the
actual antigen expression level, that is crucial for the immune
response, and underline the importance of innate stimuli in order
to form a strong immune response.
Comparing groups immunized i.d. with RREP to those
immunized with DREP, immune responses were not statistically
different (p=0.1) without E.P. When E.P. was applied, both RREP
and DREP responses increased, 2-fold and 12-fold, respectively.
The reason why the DREP-induced responses increased propor-
tionally more could potentially be because the double stranded
DREP DNA is a larger molecule (,8.0 MDa) as compared to the
single stranded RREP RNA (,3.0 MDa) and arguably has more
difficultiesenteringanintactcellularmembrane.Inaddition,DREP
needs to enter the nucleus of the cell in order to transcribe the
replicon, while RREP only needs to enter the cell cytoplasm.
Possibly, electroporation efficiently opens pores also in the nuclear
membrane and drives the DNA molecule into the nucleus.
RNA replicon-based vaccines offer a biosafe alternative to other
gene-based vaccine technologies developed to date. It does not
require a viral delivery vehicle nor does it require viral structural
genes. Thus, the hypothetical possibility of reversion or gene
conversion of the vector into a pathogenic phenotype is obviated.
Moreover, RNA-based replicon vaccines cannot integrate into the
host genome. Albeit several studies have failed to demonstrate
integrationofplasmid-based vaccines[39,40,41,42],thisstillremains
a theoretical risk that may cause regulatory authorities to delay
commercial development of DNA vaccines. Also in the absence of
genomic integration, both conventional and replicon-encoding
plasmid DNA can persist in the tissue and, depending on the
antigen, expression can be detected for months after injection
[39,41,43,44]. This raises additional concerns since persisting viral
infectionsinhumans,suchasHIVorhepatitisCvirus,areassociated
with dysfunctional CTL responses [45,46]. Correspondingly,
persisting antigen from recombinant Adenovirus vectors capable of
high level antigen expression have been shown to cause tolerization
rather than a functional immune response in certain cases [47].
In summary, intradermal administration of Semliki Forest virus
RNA replicons in combination with topical electroporation offer a
non-invasive, biosafe alternative that can be used not only in
prophylactic vaccination strategies, but also in therapeutic settings.
Supporting Information
Figure S1 Calculation of accumulated luciferase ex-
pression in vivo. This figure shows a test data-set used to
validate the formula used to calculate the accumulated luciferase
signal (Figure 2b). To calculate the integrated luciferase signal
between two time points (area under the curve) the following
formula was used: I=(t22t1)(s2+(s12s2)/2) where I is the
integrated signal, t1 is timepoint 1, t2 timepoint 2, s1 signal at
timepoint 1 and s2 signal at timepoint 2.
(TIF)
Figure S2 Analyses of memory T cell subsets. The
induction of different SIINFEKL-specific CD8
+ memory T cell
subsets was determined by CD127, CD62L, CD43 and CD27
staining 5 weeks after the last immunization. In accordance with
the results from the IFN-c ELISPOTs, SIINFEKL
+CD8
+ cells
were increased or slightly increased after boost with DREP-tLuc or
RREP-tLuc, respectively (p=0.0101 or p=0.0513, a). Central
memory (TCM; CD127
+CD62L
+, b) CD8
+ T cells were present in
the spleens of immunized mice. However, there were no
statistically significant differences in the proportions of these cells
between primed and boosted animals, neither for RREP-tLuc or
DREP-tLuc. In addition, the presence of SIINFEKL-specific
CD8
+ T cell subsets with a high recall capacity (CD27
+CD43
2,c )
was demonstrated, but with no statistically significant differences
between primed and boosted animals (c).
(TIF)
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